U.S. Markets closed

Intuitive Surgical, Inc. (ISRG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
910.36+2.79 (+0.31%)
At close: 4:00PM EDT
People also watch
  • Now we are looking for 1120 on this. That will still give 40 PE. While ADSK likes got 100.
  • Criminal Goldman indicating that the end of Dot Com II is very near. This criminal is coming out and putting super high targets on every bubble stock, just like they always to so they can short high just before the market crash.
  • Shorts annihilated
  • ISRG surgical robotics work but they are too expensive for most hospitals and require special training. A whole slew of robotic surgical devices are coming to market and many are approved and selling for a fraction of the cost.
  • I agree/ an entire new intelligence is coming/ in the end, I think this company will be antiquated, however, I can see this one going to $1000-$1100 first!
  • The shorts are getting eaten today...
  • Goldman is not playing pump and dump. Their reputation is at stake. They genuinely believe their statements because they are caught up in the "kan't lose" moment like everyone else. Even Buffett is going around telling everyone to get into stocks at these bubble levels. The real indicator for market timing is the Elliott wave count and it does not look great for ISRG going forward.


    Elliott waves vs. Goldman Sachs [ISRG]
    Today I read a recent headline attributed to Goldman Sachs indicating that Wall St. darling Intuitive Surgical (ISRG) could go to $1000 per...
  • should buy MZOR
  • What GS meant is ISRG is going to $1000 after it finds support in the $4 to $500 range.
  • Now it is time to switch to TRXC. Check the Q1, 2017 CC transcript in the link below: https://seekingalpha.com/article/4071954-transenterixs-trxc-ceo-todd-pope-q1-2017-results-earnings-call-transcript By selling 1 ISRG, one can buy 1382 TRXC.

  • I was just looking at this stock 6 months ago. After 5 years of doing nothing, my look sends it 50% higher. Wow. Do I regret not buying? Not completely. The NVDA stock I bought instead has just doubled. 67-134.
    Still, I've always wanted to own this stock.
  • another secret in this field is mzor,just starting like isrg,look at this stock.
  • I think ISRG is due for a pullback. What are your thoughts? check out aw-esomeSTOCKS, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
  • Grinding up a cancer tumour by robotics is the quickest way to spread cancer throughout the blood stream.
  • Charts pointing to 870 on this baby
  • AXSM (MC $85 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in Q3 2017 = 2000% POTENTIAL..UNKNOWN LOW FLOAT GEM !!!

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $85 Million
    Cash: $50.6 Million(cash runway into the first quarter of 2019.)

    Shares Out: 23 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation April

    HUGE Pipeline targeting Billion Dollar Markets:

    AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)

    Major Shareholders

    Herriott Tabuteau, MD 7 351 729 38,4%
    Fidelity Management & Research Co. 2 361 625 12,3%
    JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
    Mark Coleman, MD 647 998 3,38%
    BlackRock Fund Advisors 426 837 2,23%
    Stifel Trust Co., NA 415 279 2,17%
    The Vanguard Group, Inc. 272 189 1,42%
    Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
    JPMorgan Investment Management, Inc. 156 625 0,82%
    SSgA Funds Management, Inc. 134 688 0,70%

  • Do you guys believe this stock has more momentum to going upto $900? Can you also tell me some evidence of how you got your answer so i can buy it soon? Please comment it will help. Thank you
  • Short squeeze now.
  • $1000/share buyout this year.
  • They should buy MZOR and forget stock buyback.